Weight Loss Peptides: AOD-9604, 5-Amino-1MQ, and MOTS-c

Overview

AOD-9604, 5-Amino-1MQ, and MOTS-c represent three distinct approaches to pharmacological weight management that differ fundamentally from the GLP-1 receptor agonist class (semaglutide, tirzepatide) that has dominated the obesity treatment landscape. While GLP-1 drugs work primarily through appetite suppression and metabolic signaling, these three compounds target different metabolic pathways: direct lipolysis stimulation (AOD-9604), cellular energy metabolism via NNMT inhibition (5-Amino-1MQ), and mitochondrial function enhancement (MOTS-c).

It is important to state clearly at the outset: none of these compounds have the clinical evidence base that supports FDA-approved weight loss medications. The GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) have been evaluated in large-scale randomized controlled trials enrolling tens of thousands of patients, with demonstrated weight loss of 15–25% of body weight and cardiovascular benefits. The peptides discussed on this page have, at most, small early-phase human studies or only preclinical data.

This evidence gap does not mean these compounds are ineffective — it means their efficacy and safety in humans have not been rigorously established through the standard drug development process. Patients considering these peptides as alternatives to GLP-1 drugs should understand this distinction.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

At a Glance

A quick-reference overview of peptides in this category — key facts, evidence level, and estimated cost.

Head-to-Head Comparison

Sources: Heffernan et al. (2001) — AOD-9604; NNMT review (2024); Lee et al. (2015) — MOTS-c.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

AOD-9604

What It Is

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide consisting of a modified fragment of human growth hormone (hGH), specifically amino acids 177–191 of the hGH molecule. The peptide was developed by Metabolic Pharmaceuticals (now Calzada Ltd) in Australia, based on the observation that the C-terminal fragment of growth hormone retains the fat-reducing properties of GH without its growth-promoting or diabetogenic effects. A tyrosine residue is added at the N-terminus to stabilize the molecule (Heffernan et al., 2001).

Mechanism of Action

AOD-9604 mimics the lipolytic (fat-breaking) activity of growth hormone through a mechanism distinct from the GH receptor:

• Lipolysis stimulation: Enhances the breakdown of triglycerides in adipose tissue, releasing fatty acids for energy use (Heffernan et al., 2001)
• Lipogenesis inhibition: Reduces the formation of new fat from non-fat sources (de novo lipogenesis)
• No GH receptor activation: Does not bind the GH receptor and does not stimulate IGF-1 production — meaning it avoids the growth-promoting, insulin-resistance-inducing, and cancer-risk-associated effects of GH (Heffernan et al., 2001)
• Beta-3 adrenergic receptor pathway: Studies in knockout mice suggest AOD-9604's effects are mediated in part through beta-3 adrenergic receptor signaling (Heffernan et al., 2001)

Evidence

• Animal studies: Chronic treatment of obese mice with AOD-9604 produced significant weight loss and fat reduction without affecting IGF-1 levels, food intake, or glucose metabolism. Effects were also demonstrated in beta-3 adrenergic receptor knockout mice, suggesting multiple mechanisms (Heffernan et al., 2001)
• Phase 2 human trial (obesity): A Phase 2b clinical trial in obese humans showed a modest but statistically significant reduction in body weight versus placebo at one dose level after 12 weeks. However, the effect size was small
• Phase 3 failure: Metabolic Pharmaceuticals conducted a Phase 3 clinical trial for obesity that failed to meet its primary endpoint of statistically significant weight loss versus placebo. The development program for obesity was discontinued
• Osteoarthritis (Australia): AOD-9604 (under the name iTRAM) has been approved by Australia's Therapeutic Goods Administration (TGA) for intra-articular injection for knee osteoarthritis, based on evidence of cartilage-protective and anti-inflammatory effects — a completely different application than weight loss
• GRAS status (US): In 2011, AOD-9604 received Generally Recognized as Safe (GRAS) status from the FDA for use as a food ingredient — but this is not the same as FDA approval as a drug. GRAS status pertains to safety of the ingredient in food, not to therapeutic efficacy

Dosing

Dosing should be determined by a qualified healthcare provider. AOD-9604 is not FDA-approved as a drug for any indication. Clinical trials used specific doses that were not found to produce clinically meaningful weight loss in Phase 3 testing. Any use for weight loss is experimental.

Side Effects

Based on clinical trial data, AOD-9604 appears to have a relatively benign side effect profile:

• Injection site reactions (when administered subcutaneously)
• Headache
• Generally well-tolerated — no significant adverse events in clinical trials beyond placebo rates
• Does not affect blood glucose, insulin levels, or IGF-1 (Heffernan et al., 2001)

Legal Status

• United States: Not FDA-approved as a drug. Has GRAS status as a food ingredient. Available through compounding pharmacies and supplement companies. Not on the FDA Category 2 list.
• Australia: TGA-approved for intra-articular use in osteoarthritis (iTRAM). Not approved for weight loss.
• Sports: Was previously on the WADA prohibited list; status should be verified against the current year's list.

Cost

Compounded injectable AOD-9604 costs approximately $100–250/month through compounding pharmacies. Oral supplement forms are available at $30–60/month, though oral bioavailability of the peptide is uncertain.

5-Amino-1MQ (5-Amino-1-Methylquinolinium)

What It Is

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme increasingly recognized as a metabolic regulator in adipose tissue. It is technically not a peptide — it is a quinolinium derivative — but it is frequently grouped with peptide therapies in the wellness market due to its availability through similar channels (compounding pharmacies, research chemical suppliers).

NNMT is an enzyme that methylates nicotinamide (a form of vitamin B3), consuming S-adenosylmethionine (SAM) in the process. NNMT is highly expressed in adipose tissue, and its activity is elevated in obesity. By inhibiting NNMT, 5-Amino-1MQ aims to shift cellular metabolism toward greater energy expenditure (NNMT review, 2024).

Mechanism of Action

• NNMT inhibition: Blocks NNMT enzyme activity, which leads to increased intracellular NAD+ levels. NAD+ is a critical cofactor for energy metabolism — higher NAD+ activates sirtuins and other metabolic enzymes that promote fat oxidation and mitochondrial function
• SAM preservation: By preventing NNMT from consuming SAM (S-adenosylmethionine), 5-Amino-1MQ preserves methylation capacity, which is important for numerous cellular processes including gene expression regulation
• Adipocyte effects: In cell culture studies, NNMT inhibition reduced lipid accumulation in adipocytes (fat cells) and promoted a more metabolically active phenotype (NNMT review, 2024)
• No CNS appetite suppression: Unlike GLP-1 drugs, 5-Amino-1MQ does not work through appetite suppression or brain signaling pathways

Evidence

• In vitro studies: NNMT inhibition in human adipocyte cell cultures reduced lipid accumulation and shifted cellular metabolism toward greater energy expenditure (NNMT review, 2024)
• Animal studies: NNMT knockdown and pharmacological inhibition in mouse models of diet-induced obesity have shown reductions in body weight and adiposity. Mice treated with NNMT inhibitors showed decreased fat mass, improved glucose tolerance, and increased energy expenditure
• NNMT biology: The target (NNMT) is well-validated in metabolic research. Multiple groups have confirmed that NNMT expression is elevated in obesity and that its inhibition has beneficial metabolic effects in preclinical models (NNMT review, 2024)
• Human clinical trials: None published. The compound is available commercially but has not been evaluated in controlled human studies with published results

Dosing

Dosing should be determined by a qualified healthcare provider. There are no FDA-approved dosing protocols for 5-Amino-1MQ. No human clinical trial data exists to establish safe or effective doses in humans.

Side Effects

The side effect profile in humans is unknown due to the absence of clinical trial data. Preclinical studies in animal models have not reported significant toxicity, but animal safety data does not necessarily predict human safety. Anecdotal reports from users include:

• Gastrointestinal discomfort
• Headache
• Mild nausea

The lack of human safety data represents a significant uncertainty for anyone considering this compound.

Legal Status

• United States: Not FDA-approved. Not classified as a drug, dietary supplement, or controlled substance in any definitive way. Available through research chemical suppliers and some compounding pharmacies.
• International: Legal status varies. Not approved as a pharmaceutical in any jurisdiction.
• Sports: Not specifically listed on the WADA Prohibited List, though WADA's broad categories may apply.

Cost

5-Amino-1MQ oral capsules from research suppliers and compounders typically cost $80–200/month depending on dose and source. Some supplement companies sell it at $60–120/month. Quality and purity are not regulated.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c)

What It Is

MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial genome — specifically by the 12S rRNA gene. It was discovered in 2015 by researchers at the University of Southern California led by Changhan David Lee, who identified it as a mitochondrial-derived peptide (MDP) with significant metabolic regulatory functions. MOTS-c was the first mitochondrial-encoded peptide shown to have hormone-like effects on cellular metabolism throughout the body, making it a "mitochondrial hormone" or mitokine (Lee et al., 2015).

Mechanism of Action

MOTS-c exerts its metabolic effects through multiple pathways, primarily centered on AMPK activation:

• AMPK activation: MOTS-c activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. AMPK activation promotes glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and autophagy while suppressing energy-consuming processes like lipogenesis (Lee et al., 2015)
• Folate-methionine cycle: MOTS-c inhibits the folate cycle and de novo purine synthesis, leading to intracellular accumulation of AICAR (an endogenous AMPK activator). This represents an indirect mechanism of AMPK activation (Lee et al., 2015)
• Insulin sensitivity: Improves insulin signaling and glucose disposal in skeletal muscle, potentially addressing insulin resistance at a cellular level (Lee et al., 2015)
• Exercise mimetic properties: MOTS-c levels increase in skeletal muscle during exercise, and exogenous MOTS-c administration produces metabolic effects similar to exercise — including improved glucose homeostasis and fat metabolism (MOTS-c diabetes review, 2023)
• Nuclear translocation: Under metabolic stress, MOTS-c translocates to the nucleus where it regulates gene expression related to cellular stress response — a unique feature for a mitochondrial-derived peptide

Evidence

• Discovery study (rodent): The landmark 2015 paper by Lee et al. showed that MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance in mice, reduced obesity, and improved metabolic homeostasis. Mice treated with MOTS-c had reduced body weight gain, improved glucose tolerance, and lower circulating insulin levels (Lee et al., Cell Metabolism, 2015)
• Exercise physiology: MOTS-c levels in plasma and muscle increase during exercise in humans, suggesting it is part of the endogenous exercise-response signaling system (MOTS-c diabetes review, 2023)
• Aging studies: MOTS-c levels decline with age in both rodents and humans, correlating with age-related metabolic decline. This has led to investigation of MOTS-c as an anti-aging intervention (MOTS-c diabetes review, 2023)
• Phase 1 human trial: A Phase 1 clinical trial evaluating the safety and pharmacokinetics of MOTS-c in humans has been completed, with preliminary results suggesting good tolerability. Full results are awaited
• Diabetes association: Observational human studies have found that circulating MOTS-c levels are lower in patients with type 2 diabetes compared to healthy controls, suggesting a protective metabolic role (MOTS-c diabetes review, 2023)

Dosing

Dosing should be determined by a qualified healthcare provider. MOTS-c is not FDA-approved, and human dosing has not been established through the standard clinical trial and regulatory approval process. Preclinical studies used doses in animal models that are not directly translatable to human dosing.

Side Effects

Due to limited human data, the side effect profile of MOTS-c is not well established. Phase 1 trial data suggests good tolerability, but comprehensive safety data from larger trials is not available. Potential concerns include:

• Injection site reactions
• Potential effects on folate metabolism (based on mechanism — MOTS-c inhibits the folate cycle)
• Hypoglycemia risk when combined with insulin or oral diabetes medications (theoretical, based on glucose-lowering mechanism)

Legal Status

• United States: Not FDA-approved. Available through compounding pharmacies and research chemical suppliers. Not on the FDA Category 2 list. Not a controlled substance.
• International: Legal status varies. Not approved as a pharmaceutical in any jurisdiction.
• Sports: Not specifically listed on the WADA Prohibited List, though peptide hormones are broadly prohibited under S2.

Cost

Compounded MOTS-c from licensed pharmacies typically costs $150–400/month. Research-grade vials from peptide suppliers range from $60–150 per vial. As a relatively novel compound, it tends to be more expensive than more established peptides.

How These Peptides Compare to GLP-1 Drugs

Why People Seek Alternatives to GLP-1 Drugs

Despite the overwhelming evidence advantage of GLP-1 drugs, patients seek these peptide alternatives for several reasons:

• Cost: GLP-1 drugs at brand pricing ($900–1,350/month) are unaffordable for many without insurance coverage. These peptides are generally less expensive.
• Side effect intolerance: Some patients cannot tolerate GLP-1-associated GI side effects (nausea, vomiting) and seek alternatives with different mechanisms.
• Mechanism preference: Some patients and practitioners prefer approaches that enhance fat metabolism directly rather than suppressing appetite centrally.
• Access: GLP-1 drugs require a prescription and, increasingly, a specific diagnosis for insurance coverage. These peptides have been more accessible through alternative channels (though this does not make them safer or more effective).
• Combination approaches: Some practitioners use these peptides as adjuncts to GLP-1 drugs or other weight management strategies, though evidence for such combinations is lacking.

Regardless of the reason for seeking alternatives, patients should understand that choosing a compound with less clinical evidence carries inherent uncertainty about both efficacy and safety.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Sources

AOD-9604

5-Amino-1MQ / NNMT Inhibition

MOTS-c

GLP-1 Comparators